The Hemp Enforcement, Modernization, and Protection Act (H.R. 7212) establishes a comprehensive federal regulatory framework for hemp-derived cannabinoid products sold to consumers, covering everything from oral and inhalable products to topicals and edibles. The legislation requires manufacturers, processors, and importers to register their facilities with the FDA within one year and submit detailed product listings, with stricter timelines for inhalable products; it also sets mandatory labeling standards, potency limits, and safety requirements such as child-resistant packaging and quality testing. The FDA gains enforcement authority to order recalls and cease distribution of dangerous products, and must issue specific cannabinoid content limits for different product types within three years or face automatic fallback thresholds, with guidance from a new 16-member advisory committee of medical experts and industry representatives. The bill affects all businesses producing or importing cannabinoid hemp products for human consumption and protects consumers by requiring transparency on cannabinoid content, allergens, and testing results while restricting marketing to children and limiting certain ingredients deemed unsafe. No specific funding amount is mentioned in these sections, but the regulatory framework becomes effective immediately upon enactment, with most facility registration requirements completing within one year.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.